Pfizer Inc.
TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES
Last updated:
Abstract:
The invention features methods of using SFGFR3 polypeptides to treat abnormal visceral fat deposition and the conditions associated with abnormal visceral fat deposition.
Status:
Application
Type:
Utility
Filling date:
20 Sep 2018
Issue date:
24 Sep 2020